文献速递脑血管病

欧洲队列中高敏心肌肌钙蛋白I与卒中的关联:BiomarCaRE项目

Cardiac Troponin I and Incident Stroke in European Cohorts: Insights From the BiomarCaRE Project.
PubMed 文献 · Stroke · 2020-08-19

中位随访12.7年,3033人发生卒中;hsTnI浓度与总体卒中、缺血性卒中和出血性卒中风险均相关,但在经典心血管危险因素基础上加入hsTnI仅轻度改善10年卒中风险估计,可能对中等风险个体有一定价值。

要点

  • hsTnI浓度升高与总体卒中、缺血性卒中和出血性卒中风险增加相关。
  • 在经典危险因素上加入hsTnI仅轻度提高卒中风险预测的C指数。
  • 对10年卒中中等风险(5%-20%)个体,hsTnI可带来小幅净重分类改善。

核心结论

  • hsTnI浓度升高与社区人群总体卒中、缺血性卒中和出血性卒中风险增加相关。
  • 在经典心血管危险因素上加入hsTnI仅轻度改善总体队列的10年卒中风险估计,但对中等风险个体可能有一定价值。

研究设计与样本

  • 采用Cox比例风险回归评估相对风险,并通过10折交叉验证进行区分度和重分类分析以控制过度乐观。
  • 随访基于与国家住院登记和死因登记的数据链接。

主要发现

  • 中位随访12.7年,3033人发生非致死性或致死性卒中(缺血性1654例,出血性612例,不确定类型767例)。
  • 在多变量回归模型中,hsTnI浓度每增加1个标准差,总体卒中风险比为1.15(95%CI 1.10-1.21)。
  • hsTnI浓度每增加1个标准差,缺血性卒中风险比为1.14(95%CI 1.09-1.21),出血性卒中风险比为1.10(95%CI 1.01-1.20)。
  • 将hsTnI加入经典心血管危险因素后,总体、缺血性和出血性卒中的C指数分别为0.809、0.840和0.736,C指数显著但轻度提高。
  • 在10年风险为中等(5%-20%)的个体中,总体卒中的净重分类改善为0.038(P=0.021)。

临床怎么用

  • hsTnI可作为社区人群卒中风险的一个生物标志物参考,但不应单独用于风险分层。
  • 对10年卒中中等风险(5%-20%)个体,可考虑结合hsTnI辅助细化风险估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stroke is a common cause of death and a leading cause of disability and morbidity. Stroke risk assessment remains a challenge, but circulating biomarkers may improve risk prediction. Controversial evidence is available on the predictive ability of troponin concentrations and the risk of stroke in the community. Furthermore, reports on the predictive value of troponin concentrations for different stroke subtypes are scarce. METHODS: High-sensitivity cardiac troponin I (hsTnI) concentrations were assessed in 82 881 individuals (median age, 50.7 years; 49.7% men) free of stroke or myocardial infarction at baseline from 9 prospective European community cohorts. We used Cox proportional hazards regression to determine relative risks, followed by measures of discrimination and reclassification using 10-fold cross-validation to control for overoptimism. Follow-up was based upon linkage with national hospitalization registries and causes of death registries. RESULTS: Over a median follow-up of 12.7 years, 3033 individuals were diagnosed with incident nonfatal or fatal stroke (n=1654 ischemic strokes, n=612 hemorrhagic strokes, and n=767 indeterminate strokes). In multivariable regression models, hsTnI concentrations were associated with overall stroke (hazard ratio per 1-SD increase, 1.15 [95% CI, 1.10-1.21]), ischemic stroke (hazard ratio, 1.14 [95% CI, 1.09-1.21]), and hemorrhagic stroke (hazard ratio, 1.10 [95% CI, 1.01-1.20]). Adding hsTnI concentrations to classical cardiovascular risk factors (C indices, 0.809, 0.840, and 0.736 for overall, ischemic, and hemorrhagic stroke, respectively) increased the C index significantly but modestly. In individuals with an intermediate 10-year risk (5%-20%), the net reclassification improvement for overall stroke was 0.038 (P=0.021). CONCLUSIONS: Elevated hsTnI concentrations are associated with an increased risk of incident stroke in the community, irrespective of stroke subtype. Adding hsTnI concentrations to classical risk factors only modestly improved estimation of 10-year risk of stroke in the overall cohort but might be of some value in individuals at an intermediate risk.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Camen S, Palosaari T, Reinikainen J, et al. Cardiac Troponin I and Incident Stroke in European Cohorts: Insights From the BiomarCaRE Project. Stroke. 2020. PMID: 32811388. doi:10.1161/STROKEAHA.120.029452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。